SPL84 is administered directly into the lungs where it is taken up by the cells and is expected to drive the production of fully functional CFTR proteins. The Food and Drug Administration (FDA) has ...

The drug has been granted a Competitive Generic Therapy designation by the US FDA. Glenmark is recognized as the first ...

Ottawa, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The global inhaled therapy in respiratory disease market size is calculated at USD 11.98 billion in 2025 and is expected to reach around USD 16.22 billion by ...

The designation was supported by data from the multicenter, double-blind, placebo-controlled phase 3 PROMIS-I study. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...

Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S.

The tentative approval cannot take effect because a competing product was granted market exclusivity. A new formulation of treprostinil (Yutrepia) could soon be available to patients with pulmonary ...

Self treatment of the respiratory tract using inhalation nebulizer. For a patient at high risk of severe Covid-19 related complications, newly released data shows that inhaled remdesivir offers the ...

Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily activity levels, severity of symptoms or quality of life in patients with a type of heart failure for ...

Over 61.49 million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – and over 1.44 ...

A new study shows that lung stem cell secretions -- specifically exosomes and secretomes -- delivered via nebulizer, can help repair lung injuries due to multiple types of pulmonary fibrosis in mice ...